Content |
Assets
Regeneron is a biotechnology company developing life-changing drugs for people with serious medical conditions.
History
2025: Purchase of 23andMe DNA Sample Data Bank
The bankruptcy company 23andMe, which was engaged in genetic testing, will sell a data bank with DNA samples to the pharmaceutical company Regeneron Pharmaceuticals for $256 million. Bloomberg wrote about this in May 2025. The deal must be approved by the judge who handles the bankruptcy. 23andMe customers and officials demanded that the company protect the genetic data of 15 million people. Regeneron has pledged to comply with 23andMe's privacy policy, which allows customers to delete their information on request. Read more here
2022: Regeneron bought Checkmate Pharmaceuticals for $250m
In mid-April 2022, Regeneron bought the pharmaceutical company Checkmate Pharmaceuticals for $250 million to create drugs for skin cancer. The acquisition values Checkmate at $10.50 per share, four times the closing price of the company's shares on April 18, 2022 at $2.41. Read more here.
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |